fda warning about semaglutide approves Ozempic® (semaglutide) as the only GLP-1 RA to reduce the risk of worsening kidney disease and cardiovascular death in adults with type 2 diabetes and chronic kidney disease The FDA has received reports

You can select from GLP-1 drugs like liraglutide and tirzepatide

Benefits of GLP-1 Peptide Therapy for Weight Loss Scientific studies have demonstrated that GLP-1 peptide therapy can lead to significant weight loss, with patients often losing between 5% to 15% of their body weight over a year

Doctors say painful side effects, high treatment costs and inconsistent insurance coverage have kept GLP-1s away from most obese youths

Cost emerges as a central concern across all user groups

Market Entry Timeline While semaglutide patent protections expired on January 4, 2026, the regulatory approval process continues to determine when generic versions will reach pharmacy shelves

But, combining them with a structured medical weight loss program is what truly makes them work